TransMedics Group (NASDAQ:TMDX) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of TransMedics Group (NASDAQ:TMDX – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other equities analysts also recently issued reports on TMDX. Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Needham & Company LLC upped their target price on shares of TransMedics Group from $106.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday. Piper Sandler reiterated an “overweight” rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Zacks Research raised shares of TransMedics Group from a “strong sell” rating to a “hold” rating in a research report on Monday, November 2nd. Finally, Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $95.00 to $120.00 and gave the stock a “buy” rating in a report on Friday. Five investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $113.30.

Read Our Latest Report on TMDX

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $93.79 on Friday. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of 36.93, a PEG ratio of 1.00 and a beta of 2.14. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. TransMedics Group has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The firm’s 50-day simple moving average is $79.72 and its 200 day simple moving average is $92.97.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.21. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The firm had revenue of $203.01 million during the quarter, compared to analyst estimates of $178.06 million. During the same period in the previous year, the company posted $0.66 EPS. The company’s revenue for the quarter was up 41.1% on a year-over-year basis. As a group, research analysts anticipate that TransMedics Group will post 1.50 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, Director David Weill acquired 1,336 shares of the business’s stock in a transaction on Friday, September 11th. The shares were acquired at an average price of $81.63 per share, with a total value of $109,057.68. Following the completion of the transaction, the director owned 16,392 shares in the company, valued at approximately $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently made changes to their positions in TMDX. Bessemer Group Inc. raised its position in TransMedics Group by 0.5% in the third quarter. Bessemer Group Inc. now owns 46,019 shares of the company’s stock worth $3,840,000 after acquiring an additional 220 shares during the period. Hantz Financial Services Inc. boosted its stake in TransMedics Group by 56.3% in the third quarter. Hantz Financial Services Inc. now owns 827 shares of the company’s stock valued at $69,000 after acquiring an additional 298 shares during the last quarter. Harbour Investments Inc. boosted its stake in TransMedics Group by 473.7% in the third quarter. Harbour Investments Inc. now owns 3,867 shares of the company’s stock valued at $323,000 after acquiring an additional 3,193 shares during the last quarter. Allworth Financial LP grew its position in shares of TransMedics Group by 14.9% during the 3rd quarter. Allworth Financial LP now owns 2,895 shares of the company’s stock valued at $242,000 after acquiring an additional 375 shares during the period. Finally, Russell Investments Group Ltd. grew its position in shares of TransMedics Group by 19.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 19,612 shares of the company’s stock valued at $1,637,000 after acquiring an additional 3,211 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

More TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

  • Positive Sentiment: TransMedics raised its 2026 revenue outlook to $764 million–$774 million. Third-quarter revenue was $203 million, up 41% year over year, reinforcing the company’s growth outlook. TransMedics: 3 Key Takeaways for Long-Term Investors
  • Positive Sentiment: Technical indicators turned more constructive: TMDX moved above its 20-day and 50-day moving averages, which some investors may view as signs of improving short-term momentum. Zacks technical analysis
  • Neutral Sentiment: One report said TransMedics’ price target was raised to $110, potentially signaling greater upside from the level cited in the coverage. TransMedics Group Price Target Raised to $110
  • Negative Sentiment: UBS raised its target to $88 and JPMorgan to $85, but both maintained neutral ratings; the targets are below the $93.79 price cited in the reports, suggesting limited near-term upside in their view. UBS adjusts TransMedics price target

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services.

The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.

Further Reading